INDAPTUS THERAPEUTICS INC (INDP)

US45339J1051 - Common Stock

0.8891  -0.05 (-5.21%)

After market: 0.91 +0.02 (+2.35%)

INDAPTUS THERAPEUTICS INC

NASDAQ:INDP (12/23/2024, 7:09:12 PM)

After market: 0.91 +0.02 (+2.35%)

0.8891

-0.05 (-5.21%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%31.91%
Sales Q2Q%N/A
CRS7.17
6 Month-58.06%
Overview
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Ins Owners26.67%
Inst Owners5.88%
Market Cap10.68M
Shares12.01M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.5
Short Float %0.99%
Short Ratio0.67
IPO09-07 2012-09-07
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

INDP Daily chart

Company Profile

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Company Info

INDAPTUS THERAPEUTICS INC

3 Columbus Circle, 15th Floor

New York City NEW YORK

P: 16464272727

CEO: Jeffrey A. Meckler

Employees: 7

Website: https://indaptusrx.com/

INDP News

News Imagea month ago - Indaptus TherapeuticsIndaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to...

News Imagea month ago - Indaptus TherapeuticsIndaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology...

News Imagea month ago - Indaptus TherapeuticsIndaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint...

News Image2 months ago - Indaptus TherapeuticsIndaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Data further confirms Company’s “Pulse-Prime” hypothesis...

News Image2 months ago - Indaptus TherapeuticsIndaptus Therapeutics to Present at Two Upcoming Investor Conferences

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer,...

News Image4 months ago - Indaptus TherapeuticsIndaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology...

INDP Twits

Here you can normally see the latest stock twits on INDP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example